Arcus Biosciences (RCUS) Stock Forecast, Price Target & Predictions
RCUS Stock Forecast
Arcus Biosciences stock forecast is as follows: an average price target of $35.20 (represents a 110.40% upside from RCUS’s last price of $16.73) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
RCUS Price Target
The average price target for Arcus Biosciences (RCUS) is $35.20 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $44.00 to $23.00. This represents a potential 110.40% upside from RCUS's last price of $16.73.
RCUS Analyst Ratings
According to 4 Wall Street analysts, Arcus Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RCUS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Arcus Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Jason Zemansky | Bank of America Securities | $23.00 | $13.69 | 68.01% | 37.48% |
| Jul 08, 2024 | Peter Lawson | Barclays | $25.00 | $14.00 | 78.57% | 49.43% |
| Jun 24, 2024 | Asthika Goonewardene | Truist Financial | $44.00 | $16.45 | 167.48% | 163.00% |
| Jun 04, 2024 | Peter Lawson | Barclays | $35.00 | $16.15 | 116.72% | 109.21% |
| Dec 20, 2022 | - | Citigroup | $42.00 | $20.66 | 103.29% | 151.05% |
| Nov 23, 2022 | - | Citigroup | $37.00 | $27.00 | 37.04% | 121.16% |
| May 11, 2022 | Robert Driscoll | Wedbush | $42.00 | $24.01 | 74.93% | 151.05% |
The latest Arcus Biosciences stock forecast, released on Aug 09, 2024 by Jason Zemansky from Bank of America Securities, set a price target of $23.00, which represents a 68.01% increase from the stock price at the time of the forecast ($13.69), and a 37.48% increase from RCUS last price ($16.73).
Arcus Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $30.67 | $31.75 |
| Last Closing Price | $16.73 | $16.73 | $16.73 |
| Upside/Downside | -100.00% | 83.32% | 89.78% |
In the current month, the average price target of Arcus Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arcus Biosciences's last price of $16.73. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| Jul 08, 2024 | Wedbush | Buy | Buy | Hold |
| Jul 08, 2024 | Citigroup | Underperform | Underperform | Hold |
| Jul 08, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 05, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Jun 04, 2024 | Barclays | Overweight | Overweight | Hold |
| Jun 03, 2024 | Citigroup | Buy | Buy | Hold |
| Mar 25, 2024 | Robert W. Baird | Underperform | Underperform | Hold |
| Mar 25, 2024 | Wedbush | Buy | Buy | Hold |
| Feb 22, 2024 | Wedbush | Buy | Buy | Hold |
Arcus Biosciences's last stock rating was published by Bank of America Securities on Aug 09, 2024. The company gave RCUS a "Neutral" rating, the same as its previous rate.
Arcus Biosciences Financial Forecast
Arcus Biosciences Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $32.00M | $29.00M | $25.00M | $345.00K | $33.58M | - | $18.00M | $354.50M | $9.46M |
| Avg Forecast | $253.42M | $221.88M | $190.52M | $164.46M | $141.56M | $114.84M | $85.44M | $54.30M | $25.00M | $25.00M | $25.00M | $25.00M | $29.27M | $29.27M | $29.27M | $29.27M | $28.21M | $61.65M | $26.24M | $28.77M | $28.30M | $27.28M | $31.81M | $25.68M | $23.72M | $22.16M | $21.57M | $27.21M | $11.85M | $9.38M |
| High Forecast | $653.03M | $571.76M | $490.93M | $423.79M | $364.77M | $295.93M | $220.17M | $139.93M | $64.42M | $64.42M | $64.42M | $64.42M | $75.42M | $75.42M | $75.42M | $75.42M | $72.68M | $66.03M | $67.61M | $74.15M | $34.67M | $36.65M | $81.98M | $66.17M | $61.12M | $57.10M | $21.57M | $60.13M | $26.18M | $20.73M |
| Low Forecast | $111.01M | $97.20M | $83.46M | $72.04M | $62.01M | $50.31M | $37.43M | $23.79M | $10.95M | $10.95M | $10.95M | $10.95M | $12.82M | $12.82M | $12.82M | $12.82M | $12.36M | $57.92M | $11.49M | $12.60M | $23.83M | $22.50M | $13.94M | $11.25M | $10.39M | $9.71M | $21.57M | $10.18M | $4.43M | $3.51M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 9 | 6 | 4 | 3 | 7 | 5 | 2 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 0.91% | 0.97% | 0.01% | 1.52% | - | 0.66% | 29.92% | 1.01% |
Arcus Biosciences's average Quarter revenue forecast for Dec 23 based on 4 analysts is $28.30M, with a low forecast of $23.83M, and a high forecast of $34.67M. RCUS's average Quarter revenue forecast represents a -11.56% decrease compared to the company's last Quarter revenue of $32.00M (Sep 23).
Arcus Biosciences EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 9 | 6 | 4 | 3 | 7 | 5 | 2 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-80.00M | $-83.00M | $-77.00M | $-66.00M | $-62.82M | - | $-65.14M | $281.00M | $-76.43M |
| Avg Forecast | $-195.47M | $-171.14M | $-146.95M | $-126.85M | $-109.19M | $-88.58M | $-65.90M | $-41.89M | $-19.28M | $-19.28M | $-19.28M | $-19.28M | $-22.57M | $-22.57M | $-22.57M | $-22.57M | $-21.76M | $-47.55M | $-20.24M | $-50.33M | $-21.83M | $-21.04M | $-24.54M | $-53.82M | $-18.30M | $-94.00M | $-16.64M | $-57.57M | $-9.14M | $-74.31M |
| High Forecast | $-85.63M | $-74.97M | $-64.37M | $-55.57M | $-47.83M | $-38.80M | $-28.87M | $-18.35M | $-8.45M | $-8.45M | $-8.45M | $-8.45M | $-9.89M | $-9.89M | $-9.89M | $-9.89M | $-9.53M | $-44.68M | $-8.86M | $-40.26M | $-18.38M | $-17.36M | $-10.75M | $-43.06M | $-8.01M | $-75.20M | $-16.64M | $-46.05M | $-3.42M | $-59.44M |
| Low Forecast | $-503.70M | $-441.01M | $-378.66M | $-326.88M | $-281.36M | $-228.26M | $-169.82M | $-107.93M | $-49.69M | $-49.69M | $-49.69M | $-49.69M | $-58.17M | $-58.17M | $-58.17M | $-58.17M | $-56.06M | $-50.93M | $-52.15M | $-60.39M | $-26.74M | $-28.27M | $-63.23M | $-64.59M | $-47.14M | $-112.79M | $-16.64M | $-69.08M | $-20.20M | $-89.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.80% | 3.38% | 1.43% | 3.61% | 0.67% | - | 1.13% | -30.74% | 1.03% |
2 analysts predict RCUS's average Quarter EBITDA for Mar 22 to be $-57.57M, with a high of $-46.05M and a low of $-69.08M. This is -120.49% lower than Arcus Biosciences's previous annual EBITDA (Dec 21) of $281.00M.
Arcus Biosciences Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 9 | 6 | 4 | 3 | 7 | 5 | 2 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-71.00M | $-75.00M | $-80.00M | $-67.00M | $-60.44M | - | $-67.99M | $279.37M | $-77.97M |
| Avg Forecast | $73.85M | $54.12M | $34.47M | $18.34M | $4.15M | $-13.10M | $-32.60M | $-52.05M | $-68.55M | $-68.43M | $-82.85M | $-82.25M | $-97.17M | $-96.57M | $-92.62M | $-90.49M | $-110.35M | $-91.02M | $-101.58M | $-52.53M | $-93.34M | $-102.89M | $-100.06M | $-56.18M | $-103.80M | $-95.90M | $-81.13M | $-60.09M | $1.76B | $-75.81M |
| High Forecast | $225.22M | $165.07M | $105.14M | $55.93M | $12.67M | $-3.53M | $-8.78M | $-14.02M | $-18.47M | $-18.44M | $-22.32M | $-22.16M | $-26.19M | $-26.02M | $-24.96M | $-24.39M | $-29.74M | $7.41M | $-27.37M | $-42.02M | $-77.07M | $-94.70M | $-26.96M | $-44.94M | $-27.97M | $-76.72M | $-81.13M | $-48.07M | $2.12B | $-60.65M |
| Low Forecast | $19.90M | $14.59M | $9.29M | $4.94M | $1.12M | $-39.95M | $-99.41M | $-158.73M | $-209.08M | $-208.72M | $-252.67M | $-250.84M | $-296.37M | $-294.52M | $-282.48M | $-275.99M | $-336.56M | $-146.06M | $-309.79M | $-63.04M | $-122.46M | $-112.00M | $-305.16M | $-67.42M | $-316.57M | $-115.08M | $-81.13M | $-72.10M | $1.41B | $-90.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 0.75% | 1.42% | 0.65% | 0.63% | - | 1.13% | 0.16% | 1.03% |
Arcus Biosciences's average Quarter net income forecast for Mar 22 is $-60.09M, with a range of $-72.10M to $-48.07M. RCUS's average Quarter net income forecast represents a -121.51% decrease compared to the company's last Quarter net income of $279.37M (Dec 21).
Arcus Biosciences SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 9 | 6 | 4 | 3 | 7 | 5 | 2 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $30.00M | $28.00M | $30.00M | $28.00M | $26.29M | - | $23.97M | $23.30M | $16.34M |
| Avg Forecast | $220.29M | $192.87M | $165.61M | $142.96M | $123.05M | $99.83M | $74.27M | $47.20M | $21.73M | $21.73M | $21.73M | $21.73M | $25.44M | $25.44M | $25.44M | $25.44M | $24.52M | $53.59M | $22.81M | $18.52M | $24.60M | $23.72M | $27.65M | $19.81M | $20.62M | $20.10M | $18.75M | $21.19M | $10.30M | $8.16M |
| High Forecast | $567.65M | $497.00M | $426.74M | $368.38M | $317.08M | $257.24M | $191.38M | $121.64M | $56.00M | $56.00M | $56.00M | $56.00M | $65.55M | $65.55M | $65.55M | $65.55M | $63.18M | $57.40M | $58.77M | $22.23M | $30.14M | $31.85M | $71.26M | $23.77M | $53.13M | $24.12M | $18.75M | $25.42M | $22.76M | $18.02M |
| Low Forecast | $96.50M | $84.49M | $72.55M | $62.62M | $53.90M | $43.73M | $32.54M | $20.68M | $9.52M | $9.52M | $9.52M | $9.52M | $11.14M | $11.14M | $11.14M | $11.14M | $10.74M | $50.35M | $9.99M | $14.82M | $20.71M | $19.56M | $12.11M | $15.85M | $9.03M | $16.08M | $18.75M | $16.95M | $3.85M | $3.05M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.26% | 1.01% | 1.51% | 1.36% | 1.31% | - | 1.13% | 2.26% | 2.00% |
Arcus Biosciences's average Quarter SG&A projection for Dec 23 is $24.60M, based on 4 Wall Street analysts, with a range of $20.71M to $30.14M. The forecast indicates a -18.00% fall compared to RCUS last annual SG&A of $30.00M (Sep 23).
Arcus Biosciences EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 9 | 6 | 4 | 3 | 7 | 5 | 2 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.95 | $-1.02 | $-1.10 | $-0.92 | $-0.84 | - | $-0.96 | $3.97 | $-1.11 |
| Avg Forecast | $0.81 | $0.59 | $0.38 | $0.20 | $0.05 | $-0.14 | $-0.36 | $-0.57 | $-0.75 | $-0.75 | $-0.91 | $-0.90 | $-1.07 | $-1.06 | $-1.02 | $-0.99 | $-1.21 | $-1.00 | $-1.11 | $-1.01 | $-1.02 | $-1.13 | $-1.10 | $-1.16 | $-1.14 | $-1.04 | $-0.94 | $-0.85 | $-1.09 | $-1.06 |
| High Forecast | $2.47 | $1.81 | $1.15 | $0.61 | $0.14 | $-0.04 | $-0.10 | $-0.15 | $-0.20 | $-0.20 | $-0.25 | $-0.24 | $-0.29 | $-0.29 | $-0.27 | $-0.27 | $-0.33 | $0.08 | $-0.30 | $-0.27 | $-0.85 | $-1.04 | $-0.30 | $-0.31 | $-0.31 | $-0.28 | $-0.94 | $-0.16 | $-0.20 | $-0.20 |
| Low Forecast | $0.22 | $0.16 | $0.10 | $0.05 | $0.01 | $-0.44 | $-1.09 | $-1.74 | $-2.30 | $-2.29 | $-2.77 | $-2.75 | $-3.25 | $-3.23 | $-3.10 | $-3.03 | $-3.69 | $-1.60 | $-3.40 | $-3.08 | $-1.34 | $-1.23 | $-3.35 | $-3.55 | $-3.47 | $-3.17 | $-0.94 | $-2.20 | $-2.81 | $-2.72 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.84% | 0.93% | 0.95% | 0.81% | 0.81% | - | 1.12% | -3.63% | 1.05% |
According to 2 Wall Street analysts, Arcus Biosciences's projected average Quarter EPS for Mar 22 is $-0.85, with a low estimate of $-2.20 and a high estimate of $-0.16. This represents a -121.52% decrease compared to RCUS previous annual EPS of $3.97 (Dec 21).
Arcus Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.70 | $70.00 | 9900.00% | Buy |
| XFOR | X4 Pharmaceuticals | $0.70 | $3.67 | 424.29% | Buy |
| IMMX | Immix Biopharma | $1.81 | $7.00 | 286.74% | Buy |
| CNSP | CNS Pharmaceuticals | $0.15 | $0.50 | 233.33% | - |
| ITOS | iTeos Therapeutics | $12.12 | $37.67 | 210.81% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.48 | $7.00 | 182.26% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.76 | $38.80 | 181.98% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.40 | 155.26% | Buy |
| INZY | Inozyme Pharma | $5.83 | $14.67 | 151.63% | Buy |
| GPCR | Structure Therapeutics | $38.44 | $86.00 | 123.73% | Buy |
| TCRX | TScan Therapeutics | $5.45 | $12.00 | 120.18% | Buy |
| APLS | Apellis Pharmaceuticals | $35.53 | $75.38 | 112.16% | Buy |
| RCUS | Arcus Biosciences | $16.73 | $35.20 | 110.40% | Buy |
| ANNX | Annexon | $6.99 | $14.00 | 100.29% | Buy |
| CGEM | Cullinan Oncology | $17.24 | $32.00 | 85.61% | Buy |
| MDGL | Madrigal Pharmaceuticals | $233.36 | $315.75 | 35.31% | Buy |
| PTCT | PTC Therapeutics | $35.07 | $44.33 | 26.40% | Hold |
| BPMC | Blueprint Medicines | $86.51 | $101.50 | 17.33% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| KRYS | Krystal Biotech | $189.26 | $191.00 | 0.92% | Buy |
RCUS Forecast FAQ
Is Arcus Biosciences a good buy?
Yes, according to 4 Wall Street analysts, Arcus Biosciences (RCUS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of RCUS's total ratings.
What is RCUS's price target?
Arcus Biosciences (RCUS) average price target is $35.2 with a range of $23 to $44, implying a 110.40% from its last price of $16.73. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Arcus Biosciences stock go up soon?
According to Wall Street analysts' prediction for RCUS stock, the company can go up by 110.40% (from the last price of $16.73 to the average price target of $35.2), up by 163.00% based on the highest stock price target, and up by 37.48% based on the lowest stock price target.
Can Arcus Biosciences stock reach $30?
RCUS's average twelve months analyst stock price target of $35.2 supports the claim that Arcus Biosciences can reach $30 in the near future.
What are Arcus Biosciences's analysts' financial forecasts?
Arcus Biosciences's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $396.15M (high $1.02B, low $173.54M), average EBITDA is $-306M (high $-134M, low $-787M), average net income is $-93.587M (high $-13.669M, low $-297M), average SG&A $344.35M (high $887.34M, low $150.85M), and average EPS is $-1.027 (high $-0.15, low $-3.26). RCUS's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $830.29M (high $2.14B, low $363.71M), average EBITDA is $-640M (high $-281M, low $-1.65B), average net income is $180.78M (high $551.36M, low $48.72M), average SG&A $721.73M (high $1.86B, low $316.16M), and average EPS is $1.98 (high $6.05, low $0.535).
Did the RCUS's actual financial results beat the analysts' financial forecasts?
Based on Arcus Biosciences's last annual report (Dec 2022), the company's revenue was $112M, beating the average analysts forecast of $94.66M by 18.32%. Apple's EBITDA was $-264M, beating the average prediction of $-186M by 41.56%. The company's net income was $-267M, missing the average estimation of $-341M by -21.68%. Apple's SG&A was $104M, beating the average forecast of $80.66M by 28.94%. Lastly, the company's EPS was $-4.87, beating the average prediction of $-3.973 by 22.57%. In terms of the last quarterly report (Sep 2023), Arcus Biosciences's revenue was $32M, beating the average analysts' forecast of $27.28M by 17.28%. The company's EBITDA was $-80M, beating the average prediction of $-21.045M by 280.14%. Arcus Biosciences's net income was $-71M, missing the average estimation of $-103M by -30.99%. The company's SG&A was $30M, beating the average forecast of $23.72M by 26.49%. Lastly, the company's EPS was $-0.95, missing the average prediction of $-1.129 by -15.89%